Innoviva, Inc. last reported quarterly results on Nov 4, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $106.1 million (-1.6% year over year) and diluted EPS of -$1.03. It usually reports 35–56 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 24, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Feb 25, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 35–56 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 4, 2026
35 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
106
-1.6%
|
-74
-182.2%
|
-1.03
-195.4%
|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
120
+19.3%
|
-83
-231.0%
|
-1.14
-248.1%
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
98
+10.6%
|
187
+500.6%
|
2.22
+400.0%
|
|
Feb 25, 2026
56 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
115
+24.8%
|
164
+707.4%
|
1.92
+915.8%
|
|
Nov 5, 2025
36 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
108
+20.4%
|
90
+7312.0%
|
1.08
+5300.0%
|
|
Aug 6, 2025
37 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
100
+0.4%
|
64
+283.6%
|
0.77
+240.0%
|
|
May 7, 2025
37 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
89
+14.4%
|
-47
-227.5%
|
-0.74
-260.9%
|
|
Feb 26, 2025
57 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
92
+7.0%
|
20
-67.0%
|
0.19
-73.8%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INVA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Burlingame, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1080014
- Former names
- THERAVANCE INC (until Dec 7, 2015); ADVANCED MEDICINE INC (until Aug 2, 2000)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.